Richard H S Mindham

Learn More
OBJECTIVE To compare the incidence of dementia in PD with that of a control group without PD, and to assess the relationship between dementia and other features of PD. METHODS The authors recruited 83 patients with PD and 50 controls, all without dementia at initial assessment, and assessed them at regular intervals over a maximum period of 122 months.(More)
OBJECTIVE To compare the mortality rate in Parkinson's disease (PD) with a control group without PD, and to assess the relationship between mortality and features of PD. MATERIAL AND METHODS Ninety PD patients and 50 controls, mortality ascertained at 11 years follow-up. RESULTS The hazard ratio (HR) for mortality in PD patients compared with controls(More)
Serial assessments of cognition, mood, and disability were carried out at nine month intervals over a 54 month period on a cohort of 87 patients with Parkinson's disease (PD) and a matched cohort of 50 control subjects. Dementia was diagnosed from data by rigorously applying DSM-III-R criteria. Initially, 6% (5/87) PD patients were demented, compared with(More)
There is no guidance available for clinicians who have to decide on the fitness to drive of patients who have Parkinson's disease (PD). A computerised driving simulator was used to examine the effect of PD on driving ability. Ten drivers with idiopathic PD were tested as well as 10 age and sex-matched healthy drivers and four PD drivers who were no longer(More)
Tests of cognitive functions were carried out in a group of patients with Parkinson's disease and repeated after a three-year interval. Comparison was made with a control group drawn from a population of psychiatric patients, matched for age and sex. No differences in cognitive functions were found between the groups, either initially, or between those(More)
Fifty patients attending a neurological outpatient clinic for Parkinson's disease were assessed by standardized methods for both physical and psychiatric symptoms. The patients then received treatment with L-dopa with carbidopa or anticholinergic drugs and/or amantadine. During the following six-month period the subjects were assessed at intervals, both(More)
The postulated deficiency of prostaglandin E1 series (PGE1) in schizophrenia has been investigated in a controlled therapeutic trial. Twenty-one inpatients with a schizophrenic illness resistant to neuroleptic drug treatments were randomly assigned to one of three treatment conditions in a blind controlled trial of dihomo-gammalinolenic acid (DHLA), a PGE1(More)